Detection of gene marker for hormone-resistance of prostatic carcinoma

前列腺癌激素抵抗基因标志物的检测

• 批准号: 14571494
• 负责人: EHARA Hidetoshi
• 金额: $ 2.43万
• 依托单位: Gifu University School of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571494/
• 关键词: insulin-like growth factor; IGFBP-2; RT-PCR; prostate neoplasm; thymidylate synthase; dihydropyrimidine dehydrogenase; ホルモン耐性前立腺癌; マイクロアレイ; IGFBP-2; リアルタイム定量的RT-PCR

As a result of DNA microarrays for androgen-independent prostatic carcinoma cell line (LNCaP-N) established in our laboratory, LNCap-N strongly expressed insulin like growth factor-binding protein 2 (IGFBP-2) compared with androgen-dependent parent cell line (LNCaP). Therefore we investigated the expressions of IGFBP-2 in human prostate diseases by real time quantitative RT-PCR method.Archival samples were obtained from prostate needle biopsy specimens in 39 BPH cases and 69 nontreatment-prostatic carcinoma cases. In 21 prostate carcinoma cases treated hormone therapy, archival samples were obtained from transurethral resection. The IGFBP-2 expression levels in BPH cases was statistically higher than those in no-treated prostate carcinoma cases (P<0.0001). In prostate carcinomas, there was no difference between the IGFBP-2 expression levels of low-grade cases and those of high-grade cases. And, we did not show significant difference between the IGFBP-2 expression levels of localized cases and those of advanced cases. Moreover, the IGFBP-2 expression levels did not associated to the cause-specific survival rate and recurrence rate. On the other hand, we compared the IGFBP-2 expression levels with ileum bone marrow and with primary tumor lesion in 4 metastatic prostatic carcinoma cases, and that of bone marrow tended to be low than that of primary tumor. In 21 cases performed hormone therapy, the IGFBP-2 expression levels were higher than those of no-treated carcinoma cases. These results showed statistically significant difference (P=0.0158).Furthermore, we studyed mRNA expression level of thymidylate synthase and dihydropynmidine dehydrogenase for prostatic carcinoma, but did not recognize the correlation between clinicopathologic factor.

我们实验室建立的雄激素非依赖性前列腺癌细胞系（LNCaP-N）的DNA微阵列结果显示，与雄激素依赖性亲本细胞系（LNCaP）相比，LNCap-N强烈表达胰岛素样生长因子结合蛋白2（IGFBP-2）。因此，我们通过实时定量RT-PCR方法研究了IGFBP-2在人类前列腺疾病中的表达。档案样本取自39例BPH病例和69例未治疗的前列腺癌病例的前列腺穿刺活检标本。在接受激素治疗的 21 例前列腺癌病例中，档案样本来自经尿道切除术。 BPH病例中IGFBP-2的表达水平显着高于未治疗的前列腺癌病例（P<0.0001）。在前列腺癌中，低级别病例和高级别病例的IGFBP-2表达水平没有差异。而且，我们没有发现局限性病例和晚期病例的 IGFBP-2 表达水平存在显着差异。此外，IGFBP-2表达水平与病因特异性生存率和复发率无关。另一方面，我们比较了4例转移性前列腺癌病例中IGFBP-2与回肠骨髓和原发肿瘤病灶的表达水平，骨髓的IGFBP-2表达水平往往低于原发肿瘤。 21例接受激素治疗的癌症病例中，IGFBP-2表达水平高于未治疗的癌症病例。这些结果具有统计学显着性差异(P=0.0158)。此外，我们研究了前列腺癌胸苷酸合酶和二氢吡脒脱氢酶的mRNA表达水平，但没有认识到临床病理因素之间的相关性。

项目成果

Hidetoshi Ehara et al.: "Expression of mitotic Aurora/ Ipl1p-related kinases in renal Cell carcinoma : an immunohistochemical study"Urological Research. 31. 382-386 (2003)

Hidetoshi Ehara 等人：“肾细胞癌中有丝分裂 Aurora/Ipl1p 相关激酶的表达：一项免疫组织化学研究”泌尿学研究。

Hidetoshi Ehara et al.: "Expression of mitotic Aurora/Ipl1p-related kinases in renal Cell carcinoma : an immunohistochemical study"Urological Research. 31. 382-386 (2003)

Hidetoshi Ehara 等人：“肾细胞癌中有丝分裂 Aurora/Ipl1p 相关激酶的表达：一项免疫组织化学研究”泌尿学研究。

Hidetoshi Ehara, et al.: "Expression of mitotic Aurola/lpl1p-related kinase in renal cell carcinoma : an immunohistochemical study."Urological Research. 31. 382-386 (2003)

Hidetoshi Ehara 等人：“肾细胞癌中有丝分裂 Aurola/lpl1p 相关激酶的表达：一项免疫组织化学研究。”泌尿学研究。